Abivax SA

Abivax SA’s advancing HIV, hepatitis B and other antiviral pipeline, coupled with takeover speculation, is driving investor optimism and share‑price momentum.

Abivax SA, a Paris‑based biotech, is pushing anti‑viral therapy and vaccine development, with key Phase II candidates like ABX 464 for HIV and ABX 203 for hepatitis B, while navigating volatile market trends.

Abivax SA

Abivax SA: How a French biotech’s anti‑viral pipeline is riding a health‑care rotation and what clinical milestones could spark its next growth surge.

Abivax SA sees renewed investor confidence as Truist Securities issues a buy rating, backed by a strong pipeline of antiviral and therapeutic vaccines targeting high‑growth markets in Asia and Latin America.

Abivax SA successfully raised $747.5 million in capital and saw its stock price surge 586% after announcing positive Phase-3 data for its Colitis Ulcerosa treatment candidate.

Abivax SA’s stock surged by 48% after positive late-stage trial results for its ulcerative colitis treatment, obefazimod, and a significant capital increase.

Abivax SA’s stock price surged over 500% after the company announced positive results from its Phase 3 clinical trials for its ulcerative colitis drug, Obefazimod.

Abivax SA, a Paris-based biotech firm, navigates financial uncertainty while advancing its innovative pipeline of anti-viral therapies and vaccines.